Zylo Therapeutics
Greenville, US · Founded 2017 · Delaware corporation · 3 known investors
Zylö Therapeutics develops therapeutic delivery technology, focusing on product development in the biotech and drug-delivery space.
Founders & leadership
Zylo Therapeutics was founded in 2017 by Scott R. Pancoast.
Investors · 3
Reported raises · per SEC filings
Form D private placements$4.9M disclosed across 2 of 3 rounds · 2017–2021
▶$1.5MraisedJul 2021 · 12 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedJul 2021 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LANCE MICHAEL WHITEDirector
- James CordesDirector
- SCOTT RUTLEDGE PANCOASTExecutive Officer, Director
- Matt DunbarDirector
- GARY J. ATKINSONDirector
- Charles E. HinkleExecutive Officer
- Offering amount
- $3.2M
- Amount sold
- $1.5M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3.4MraisedJun 2019 · 32 investors · PharmaceuticalsRule 506(b)
▶$3.4MraisedJun 2019 · 32 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LANCE MICHAEL WHITEDirector
- SCOTT RUTLEDGE PANCOASTExecutive Officer, Director
- GARY J. ATKINSONDirector
- MICHAEL ZVI RABINExecutive Officer
- Offering amount
- $4M
- Amount sold
- $3.4M
- Proceeds to insiders
- $513K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$6MofferedNov 2017 · 4 investors · PharmaceuticalsRule 506(b)
▶$6MofferedNov 2017 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott Rutledge PancoastExecutive Officer, Director, Promoter
- Thomas Patrick MurrayExecutive Officer
- Lance Michael WhiteDirector
- Gary J AtkinsonDirector
- Offering amount
- $6M
- Minimum investment
- $10K
- Proceeds to insiders
- $1.4M
- First sale
- Oct 2017
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Xylo8 shared keywordsXylo develops mechanism-based drug therapies targeting psychiatric and neurological disorders using computational and rational drug design approaches. The company serves patients and healthcare systems seeking novel treatments for complex neuropsychiatric conditions.
Xilio Therapeutics5 shared keywordsXilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
Zylo5 shared keywordsZylo provides SaaS and AI spend management software that discovers, tracks, and optimizes enterprise software spending by analyzing financial data and using AI models trained on over $75 billion in transaction data. The platform is designed for enterprise organizations to gain complete visibility and control over their software spend across multiple business units and applications.
Sentynl4 shared keywordsA biopharmaceutical company developing novel medicines for rare diseases, serving patients and caregivers from early detection through therapeutic intervention.
Applied Therapeutics4 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Seelos Therapeutics4 shared keywords
Companies competing with Zylo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $147.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $263.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Zylo Therapeutics do?
- Zylö Therapeutics develops therapeutic delivery technology, focusing on product development in the biotech and drug-delivery space.
- Who founded Zylo Therapeutics?
- Zylo Therapeutics was founded by Scott R. Pancoast in 2017.
- Who are Zylo Therapeutics's investors?
- Zylo Therapeutics's investors include AEON Foundry, Boston Harbor Angels, HBS Angels of Boston.
- How much funding has Zylo Therapeutics raised?
- Zylo Therapeutics has disclosed $4.9M raised across 2 of its 3 known rounds.
- Where is Zylo Therapeutics headquartered?
- Zylo Therapeutics is headquartered in Greenville, US.